SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as a forthcoming city council vote on a massive data center project in Independence, Missouri, sparks heated community debate over economic benefits versus local concerns. Investors are also actively discussing the stock's market correlation with a competitor's recent earnings, despite many highlighting NBIS's stronger financial position within the AI infrastructure sector.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as escalating geopolitical tensions in the Middle East, particularly concerns around the Strait of Hormuz and broader oil supply, fuel significant bullish sentiment across the energy sector. The community is actively discussing INDO's potential for a substantial rally and short squeeze, anticipating higher oil prices to persist for weeks.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is surging due to escalating Middle East tensions driving up oil prices, fueling a massive short squeeze as the community speculates on significant upside and debates the implications of the Strait of Hormuz situation.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending following its recent full-year earnings report, which highlighted record revenue, a significant profitability turnaround, and a massive AI infrastructure pipeline, driving strong community discussion about its perceived undervaluation despite some lingering skepticism regarding past execution and stock performance.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

Hydrograph Clean Power (HGRAF) is surging after securing regulatory clearances from the US EPA, UK, and EU for commercial graphene sales, removing a major bottleneck and fueling intense community discussion about its high-purity material and anticipated contracts. The recent oversubscribed capital raise further signals market confidence in its path to industrial execution and rapid expansion.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is seeing significant investor interest following a robust Q4 earnings beat and a favorable legal outcome against Shell, while broader sentiment is fueled by surging global LNG prices due to escalating Middle East tensions impacting supply. The community is actively discussing the stock's perceived undervaluation, potential for a short squeeze, and its strong positioning to capitalize on high spot market prices.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as the community anticipates a Bankable Feasibility Study (BFS) update for its Tanbreez heavy rare earth project in Greenland, with discussions centered on its strategic importance for US national security and defense, amidst escalating global tensions and China's rare earth dominance.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending due to a significant after-hours sell-off following its Q4 earnings, where a beat on revenue and EPS was overshadowed by weaker-than-expected guidance and leadership departures. The community is debating if the sharp drop is an "overblown" reaction and a "buy the dip" opportunity, or if it reflects concerns over the SaaS sector's outlook and prior valuation.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending after a Raymond James downgrade to Underperform, citing uncertainty around the Space Force's SCAR program, its largest contract, which triggered a sharp intraday decline. The community is actively debating whether the sell-off is an overreaction and market manipulation or a legitimate concern for the defense drone leader.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as the FDA lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial, with the patient death now attributed to an ulcer rather than the CRISPR-based therapy. The community is actively discussing a significant short squeeze potential due to high short interest, with many seeing the stock as undervalued and this development as a positive signal for the broader gene-editing industry.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Commit To Buy Terns Pharmaceuticals At $30, Earn 34% Using Options

Investors considering a purchase of Terns Pharmaceuticals Inc (Symbol: TERN) shares, but tentative about paying the going market price of $39.66/share, might benefit from considering selling puts...

Viatris Stock to Report Q4 Earnings: What's in the Cards?

VTRS gears up for Q4 results amid Indore import alert, segment revenue pressure and steady margins as shares surge 39.7% in a year.

Terns Pharmaceuticals (NASDAQ:TERN) Raised to "Strong-Buy" at TD Cowen

TD Cowen raised Terns Pharmaceuticals to a "strong-buy" rating in a report on Friday...

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing

Key PointsORBIMED Advisors LLC reduced stake by 5,409,671 shares in Terns Pharmaceuticals; the estimated trade size is $125.01 million based on quarterly average price...

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of "Moderate Buy" by Brokerages

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the firm, Marketbeat...

Terns Pharmaceuticals (NASDAQ:TERN) CEO Sells $571,507.77 in Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy Burroughs sold 14,583 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price...

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge

Key PointsFirst Turn Management acquired 872,049 shares in Terns Pharmaceuticals during the fourth quarter...

Terns Pharmaceuticals (NASDAQ:TERN) Upgraded at Wall Street Zen

Wall Street Zen raised shares of Terns Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday...

Leerink Partners Begins Coverage on Terns Pharmaceuticals (NASDAQ:TERN)

Leerink Partners started coverage on shares of Terns Pharmaceuticals in a report on Monday. They issued an "outperform" rating and a $58.00 target price on the stock...

Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High?

The consensus price target hints at a 50.9% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.29	--	--	N/A
Q3 '25	-$0.30	-$0.27	9.02%	BEAT
Q2 '25	-$0.29	-$0.26	10.45%	BEAT
Q1 '25	-$0.29	-$0.26	11.54%	BEAT
Q4 '24	-$0.31	-$0.24	21.61%	BEAT

TERN
Terns Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest TERN News

TERNTerns Pharmaceuticals Inc